THE GROWTH HORMONE-RELEASING ACTIVITY OF HEXARELIN, A NEW SYNTHETIC HEXAPEPTIDE, IN SHORT NORMAL AND OBESE CHILDREN AND IN HYPOPITUITARY SUBJECTS

Hexarelin (Hex) is a new synthetic hexapeptide with potent growth horm one (GH)-releasing activity in both animals and men. we evaluated the GH response to a maximal dose of Hex (2 mu g/kg iv) and GH-releasing h ormone (GHRH) (1-29, 1 mu g/kg iv) in 45 short normal children (24 mal es and 21 females, age 5.9-14 yr, 24 prepubertal and 21 in Tanner stag e 2 or 3 of pubertal maturation), in 10 prepubertal obese children (7 males and 3 females, age 7.5-12 yr), and in 5 subjects with organic hy popituitarism (4 males and 1 female, age 8.4-21 yr). In 5 male subject s with constitutional growth delay (age 12.0-13.7 yr), the GH response to Hex was reevaluated 1 week after priming with testosterone enantha te (100 mg im). In all short normal children Hex caused a prompt and c lear-cut increase of serum GH concentrations, with peaks occurring bet ween 15-30 min from injection. The GH response to Hex was significantl y higher than that observed after GHRH and was not different between m ales and females or between prepubertal and pubertal subjects. Priming with testosterone resulted in an increased GH response to Hex in all 5 subjects studied. No GH increase was observed in the hypopituitary s ubjects after either GHRH or Hex administration. In the obese children the GH responses to GHRH and to Hex were significantly lower than in the prepubertal children. Also, in the obese, the GH response to Hex w as significantly higher than that observed after GHRH. In all short no rmal and obese children, but not in the hypopituitary subjects, Hex ad ministration caused a slight but significant increase from baseline of both cortisol and PRL concentrations that returned to the baseline va lues within 2 h. None of the subjects experienced adverse side effects after Hex administration. This study shows that, in short normal and obese children, Hex is a potent GH-releasing stimulus with potential c linical utility.